Liu WN, Dai MS, Lin F, Lin GM. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors. World J Gastroenterol 2024; 30(21): 2748-2750 [PMID: 38899330 DOI: 10.3748/wjg.v30.i21.2748]
Corresponding Author of This Article
Gen-Min Lin, FACC, FAHA, FESC, MD, PhD, Academic Editor, Academic Fellow, Chief Physician, Department of Medicine, Hualien Armed Forces General Hospital, No. 100 Jinfeng Street, Hualien City 970, Taiwan. farmer507@yahoo.com.tw
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 7, 2024; 30(21): 2748-2750 Published online Jun 7, 2024. doi: 10.3748/wjg.v30.i21.2748
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors
Wei-Nung Liu, Ming-Shen Dai, Felicia Lin, Gen-Min Lin
Wei-Nung Liu, Department of Medicine, Tri-Service General Hospital, Taipei 114, Taiwan
Ming-Shen Dai, Division of Hematology/Oncology, Department of Internal Medicine, National Defense Medical Center, Taipei 114, Taiwan
Felicia Lin, Community Care, Minnesota Oncology, Minneapolis, MN 55404, United States
Gen-Min Lin, Department of Medicine, Hualien Armed Forces General Hospital, Hualien City 970, Taiwan
Author contributions: Liu WN wrote the article; Dai MS, Lin F, and Lin GM made critical revisions related to important content of the manuscript; and all authors provided approval of the final version of the article to be published.
Conflict-of-interest statement: All authors declared to have conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gen-Min Lin, FACC, FAHA, FESC, MD, PhD, Academic Editor, Academic Fellow, Chief Physician, Department of Medicine, Hualien Armed Forces General Hospital, No. 100 Jinfeng Street, Hualien City 970, Taiwan. farmer507@yahoo.com.tw
Received: March 5, 2024 Revised: April 26, 2024 Accepted: May 11, 2024 Published online: June 7, 2024 Processing time: 90 Days and 6 Hours
Abstract
In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.
Core Tip: This is an invited editorial for the coming paper “Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis”.
